APOC3 and hypertriglyceridemia: Olezarsan: The Bridge-TIMI 73a trial by Bergmark et al. demonstrated a novel drug called olezarsan, an ASO that targets APOC3 mRNA, as an effective candidate for reducing TG and APOC3 in patients with moderate to severe hypertriglyceridemia. Their randomized placebo-controlled phase 2b study demonstrated TG levels reduction by 49.3% (95% CI: 39.5 to 59.0) and 53.1% (95% CI: 43.4 to 62.9) at 50 mg and 80 mg, respectively, at six months (p < 0.001 for both).